Pfizer Weighing FDA Request to Change Zoloft's Warnings

Corrected
  • FDA suggests altering warnings on congenital cardiac defects
  • Pfizer faces hundreds of lawsuits over the antidepressant

The U.S. Food and Drug Administration wants Pfizer Inc. to modify safety warnings for its antidepressant Zoloft and acknowledge for the first time that some studies linked the mood-altering medication to heart defects in newborns. The body of evidence on the drug still finds no tie to birth defects.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.